Your browser doesn't support javascript.
loading
A multicenter phase Ib trial of the histone deacetylase inhibitor entinostat in combination with pembrolizumab in patients with myelodysplastic syndromes/neoplasms or acute myeloid leukemia refractory to hypomethylating agents.
Bewersdorf, Jan Philipp; Shallis, Rory M; Sharon, Elad; Park, Silvia; Ramaswamy, Rahul; Roe, Caroline E; Irish, Jonathan M; Caldwell, Anne; Wei, Wei; Yacoub, Abdulraheem; Madanat, Yazan F; Zeidner, Joshua F; Altman, Jessica K; Odenike, Olatoyosi; Yerrabothala, Swaroopa; Kovacsovics, Tibor; Podoltsev, Nikolai A; Halene, Stephanie; Little, Richard F; Piekarz, Richard; Gore, Steven D; Kim, Tae Kon; Zeidan, Amer M.
Afiliación
  • Bewersdorf JP; Section of Hematology, Department of Internal Medicine, Yale Cancer Center, Yale School of Medicine, Yale University, New Haven, CT, USA. jan.bewersdorf@yale.edu.
  • Shallis RM; Leukemia Service, Memorial Sloan Kettering Cancer Center, New York, NY, USA. jan.bewersdorf@yale.edu.
  • Sharon E; Section of Hematology, Department of Internal Medicine, Yale Cancer Center, Yale School of Medicine, Yale University, New Haven, CT, USA.
  • Park S; Cancer Therapy Evaluation Program, National Cancer Institute, Bethesda, MD, USA.
  • Ramaswamy R; Division of Hematology/Oncology, Vanderbilt University Medical Center, Nashville, TN, USA.
  • Roe CE; Division of Hematology/Oncology, Vanderbilt University Medical Center, Nashville, TN, USA.
  • Irish JM; Department of Cell and Developmental Biology, Vanderbilt University, Nashville, TN, USA.
  • Caldwell A; Department of Pathology, Microbiology and Immunology, Vanderbilt University Medical Center, Nashville, TN, USA.
  • Wei W; Vanderbilt Center for Immunobiology, Vanderbilt University, Nashville, TN, USA.
  • Yacoub A; Department of Cell and Developmental Biology, Vanderbilt University, Nashville, TN, USA.
  • Madanat YF; Department of Pathology, Microbiology and Immunology, Vanderbilt University Medical Center, Nashville, TN, USA.
  • Zeidner JF; Vanderbilt Center for Immunobiology, Vanderbilt University, Nashville, TN, USA.
  • Altman JK; Section of Hematology, Department of Internal Medicine, Yale Cancer Center, Yale School of Medicine, Yale University, New Haven, CT, USA.
  • Odenike O; Section of Hematology, Department of Internal Medicine, Yale Cancer Center, Yale School of Medicine, Yale University, New Haven, CT, USA.
  • Yerrabothala S; The Division of Hematologic Malignancies and Cellular Therapeutics (HMCT), The University of Kansas Cancer Center, Westwood, KS, USA.
  • Kovacsovics T; Harold C. Simmons Comprehensive Cancer Center, UT Southwestern Medical Center, Dallas, TX, USA.
  • Podoltsev NA; Lineberger Cancer Center, University of North Carolina, Chapel Hill, NC, USA.
  • Halene S; Robert H. Lurie Comprehensive Cancer Center of Northwestern University, Chicago, IL, USA.
  • Little RF; University of Chicago, Chicago, IL, USA.
  • Piekarz R; Hitchcock Cancer Center, Dartmouth University, Lebanon, NH, USA.
  • Gore SD; University of Utah, Huntsman Cancer Center, Salt Lake City, UT, USA.
  • Kim TK; Section of Hematology, Department of Internal Medicine, Yale Cancer Center, Yale School of Medicine, Yale University, New Haven, CT, USA.
  • Zeidan AM; Section of Hematology, Department of Internal Medicine, Yale Cancer Center, Yale School of Medicine, Yale University, New Haven, CT, USA.
Ann Hematol ; 103(1): 105-116, 2024 Jan.
Article en En | MEDLINE | ID: mdl-38036712

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Síndromes Mielodisplásicos / Leucemia Mieloide Aguda Límite: Humans Idioma: En Revista: Ann Hematol Asunto de la revista: HEMATOLOGIA Año: 2024 Tipo del documento: Article País de afiliación: Estados Unidos

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Síndromes Mielodisplásicos / Leucemia Mieloide Aguda Límite: Humans Idioma: En Revista: Ann Hematol Asunto de la revista: HEMATOLOGIA Año: 2024 Tipo del documento: Article País de afiliación: Estados Unidos